Cannabis Law and Access in Georgia

Georgia's cannabis framework: one of the stranger legal arrangements on the planet

Roughly 2,800 kilometres from Canberra , as the crow flies, not that any crow is making that trip , sits a country whose cannabis laws have been quietly fascinating legal researchers for nearly a decade. Georgia, the South Caucasus nation bordered by Russia, Turkey, Armenia, and Azerbaijan, holds what I'd genuinely describe as one of the most internally contradictory cannabis legal frameworks in the world. Consumption has been decriminalised by constitutional ruling. Cultivation and sale remain criminal offences. And the whole situation persists in a kind of unresolved tension that neither legislators nor courts have fully untangled.

I came across Georgia's framework whilst researching comparative access pathways for a piece on how different jurisdictions handle the gap between permissive constitutional rulings and restrictive statute law. I'll admit I spent a Saturday afternoon in a rabbit hole , Trevor (my sourdough starter) was very much neglected; reading through the Georgian Constitutional Court decisions and cross-referencing them against the country's Criminal Code. It's a genuinely unusual case study.

The 2018 Constitutional Court ruling: what it actually said

In July 2018, Georgia's Constitutional Court ruled that criminalising the personal consumption of cannabis was unconstitutional. The case was brought under Article 16 of Georgia's Constitution, which protects the right to free personal development. The court found that punishing an adult for consuming a substance that harms only themselves, in private, was a disproportionate restriction on personal autonomy.

That ruling decriminalised consumption specifically. It did not legalise cannabis. It did not decriminalise possession, cultivation, or supply. Those distinctions matter enormously, and they're where the framework gets genuinely strange.

A person in Georgia can, in theory, consume cannabis without criminal liability. But obtaining it; purchasing it, growing it, or being found with it in a form that implies possession rather than mere consumption, remains a criminal matter under the Georgian Criminal Code. The court created a right to consume without creating any lawful means of access to the substance being consumed. If that sounds structurally absurd, that's because it is. I'd argue it represents a classic case of judicial reform outpacing legislative will, and the Georgian parliament has shown little urgency in resolving it.

What the criminal code still prohibits

Georgia's Criminal Code continues to classify cannabis as a controlled substance. Relevant provisions impose significant penalties for:

• Illegal acquisition or possession (separate from the act of consumption itself)
• Cultivation of cannabis plants
• Sale, supply, or trafficking
• Import or export

Penalties scale with quantity and intent. Possession of cannabis above defined threshold amounts, which have been revised by the Georgian parliament in the years following the 2018 ruling; can attract custodial sentences. The thresholds themselves have shifted more than once, reflecting ongoing political back-and-forth between more liberal and more conservative factions in the Georgian Dream-dominated parliament.

Administrative (non-criminal) fines had previously applied to smaller possession amounts, but the legal picture around what quantity triggers what response has not been entirely stable. For anyone researching this for genuine legal purposes, the current Georgian Criminal Code text and associated government commentary is the only reliable reference, and consulting a Georgian lawyer is the only sensible course.

Medical cannabis: a separate, limited pathway

Georgia has a limited medical cannabis framework, though it bears little resemblance to the more developed access systems in places like Australia or Germany. Hemp-derived products with low tetrahydrocannabinol (THC) content have had some regulatory space, and there have been legislative moves, some partial, some stalled; to create a broader framework for cannabis-based medicines.

The government has at various points signalled interest in developing a licensed medical cannabis industry, partly for export potential. But as of the time of writing, Georgia does not have a fully operational, well-defined medical cannabis access pathway comparable to Australia's Special Access Scheme or Authorised Prescriber route. The regulatory architecture simply isn't there at the same level of detail.

What does exist is a hemp industry framework. Georgia passed legislation permitting licensed cultivation of industrial hemp, defined by THC content, and there has been commercial activity in hemp fibre and hemp-derived extracts. The distinction between hemp-derived cannabidiol (CBD) products and higher-THC cannabis products is, as in most jurisdictions, the key regulatory dividing line.

The Rustavi 2 protests and political context

You can't fully understand Georgia's cannabis policy without a word on the political backdrop. The 2018 ruling emerged partly from sustained civil society pressure, particularly from younger, urban Georgians who saw cannabis enforcement as emblematic of a broader authoritarian approach to personal freedoms. Protest movements and media coverage; including reporting by Rustavi 2, one of Georgia's most prominent television networks, helped build public pressure that contributed to the legal challenge reaching the Constitutional Court.

Since then, Georgian politics has remained turbulent. The governing Georgian Dream party has not moved to fully legalise or regulate cannabis, and the official stance has oscillated. Legislative proposals to tighten restrictions have occasionally emerged, though none have comprehensively reversed the Constitutional Court's ruling, which would require either a new constitutional challenge or a constitutional amendment.

How this compares to the Australian framework

For Australian readers used to thinking about cannabis access through the lens of the Therapeutic Goods Administration and the Poisons Standard, Georgia's framework is a useful contrast. In Australia, cannabis products for human use are scheduled under the Poisons Standard. THC-containing products are Schedule 8 controlled drugs requiring a prescription and specific state/territory permits. Low-dose CBD products meeting defined criteria are Schedule 3 (pharmacist-only). The pathways are the TGA's Special Access Scheme and the Authorised Prescriber programme; structured, documented, and heavily regulated.

Georgia has no equivalent scheduling architecture, no TGA-style regulator for cannabis, and no formalised prescribing pathway with the same depth of oversight. The constitutional decriminalisation of consumption is, in some ways, more liberal than anything in Australian law, personal adult consumption of cannabis in private is not a criminal matter in Georgia in a way it still is in most Australian states. But the complete absence of a lawful supply chain is, arguably, a worse outcome for anyone seeking reliable, quality-controlled access to cannabis-based products for any purpose.

The endocannabinoid system doesn't change depending on which country you're in; the regulatory context around it very much does. Understanding cannabinoid chemistry, including how compounds like CBD interact with CB1 and CB2 receptors; is the same science in Tbilisi as in Sydney. What differs entirely is what the law permits, prohibits, and in Georgia's case, leaves unresolved.

What this means for researchers and policy watchers

Georgia is genuinely worth watching if you follow comparative cannabis law. A few things make it interesting from a policy perspective:

• It's one of the only countries where decriminalisation of consumption came through a constitutional rights ruling rather than legislative reform. That's a different legal mechanism with different implications for durability.
• The persistent gap between consumption rights and supply legality is a live policy problem. Some scholars argue it creates worse outcomes than either full prohibition or full legalisation, because it removes criminal liability for the end user while leaving the entire supply chain in criminal hands.
• Georgia's geographic position, a transit corridor between Europe, Central Asia, and the Middle East, makes its cannabis policy internationally relevant beyond its domestic population of around 3.7 million people.

The EMCDDA (European Monitoring Centre for Drugs and Drug Addiction) has profiled Georgia's policy in its comparative country reporting, and academic work on post-Soviet cannabis law reform has looked at Georgia as a case study. Neither the EMCDDA profile nor the academic literature suggests Georgia is close to a comprehensive legislative resolution.

Whether that changes will depend partly on domestic politics, partly on EU accession aspirations; Georgia was granted EU candidate status in December 2023, and partly on how European norms around cannabis continue to evolve. It's a story still in motion.

Sources

• Georgia Drug Report 2023, European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)
• Cannabis; United Nations Office on Drugs and Crime (UNODC)
• Guidance on access to unapproved therapeutic goods: medicinal cannabis in Australia, Therapeutic Goods Administration (TGA)
• Cannabis policy in former Soviet states, National Center for Biotechnology Information (NCBI)

, Marcus Hale, Regulatory researcher; TGA & access law